Latest news with #CatalystPharmaceuticals
Yahoo
4 days ago
- Business
- Yahoo
Zacks.com featured highlights Catalyst Pharmaceuticals, SunOpta, Gambling.com and Orion Group
For Immediate Release Chicago, IL – July 24, 2025 – The stocks in this week's article are Catalyst Pharmaceuticals, Inc. CPRX, SunOpta Inc. STKL, Group Ltd. GAMB and Orion Group Holdings, Inc. ORN. Rising Cash Flows Make These 4 Stocks Worth Choosing Now We are already into the second-quarter reporting cycle, and stocks with top-line growth and increasing profit numbers might be popular choices. Moreover, choosing stocks based on a company's efficiency in generating cash flows can be far more rewarding. In this regard, stocks such as Catalyst Pharmaceuticals, Inc., SunOpta Inc., Group Ltd. and Orion Group Holdings, Inc. are worth buying. This is because even a profit-making company can have a dearth of cash flow and become bankrupt while meeting its obligations if its profits are not channeled in the right direction. However, a company can effectively weather any market mayhem if it has a solid cash position, as that lends a company the flexibility to make decisions, the means to invest and the fuel to run its growth engine. It is indeed the key to a company's existence, development and success and reveals its true financial health. Furthermore, with uncertainties in the global economy, market disruptions and dislocations, as well as liquidity concerns, analyzing a company's cash-generating efficiency holds more relevance. To figure out this efficiency, one needs to consider a company's net cash flow. While in any business, cash moves in and out, it is net cash flow that explains how much money a company is actually generating. If a company is experiencing a positive cash flow, it denotes an increase in its liquid assets, which gives it the means to meet debt obligations, shell out for expenses, reinvest in the business, endure downturns and finally return wealth to shareholders. On the other hand, a negative cash flow indicates a decline in the company's liquidity, which in turn lowers its flexibility to support these moves. However, having a positive cash flow merely does not secure a company's future growth. To ride on the growth curve, a company must have its cash flow increasing because that indicates management's efficiency in regulating its cash movements and less dependency on outside financing for running its business. Therefore, keep yourself abreast with the following screen to bet on stocks with rising cash flows. Here are four out of the six stocks that qualified for the screening: Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases. The Zacks Consensus Estimate for Catalyst Pharmaceuticals' 2025 earnings has been revised upward by 2 cents to $2.25 per share in the past 60 days. CPRX has a VGM Score of A. SunOpta provides tailored supply-chain innovations and solutions to leading brands, retailers and foodservice companies, spanning a wide range of beverages, broths and nutritious snack offerings. The Zacks Consensus Estimate for SunOpta's 2025 EPS is pegged at 18 cents, suggesting a surge of 63.6% from the year-ago reported figure. STKL has a VGM Score of B. offers marketing and sports data services to the global online gambling industry. It supports iGaming and sports betting operators in acquiring customers across 19 national markets and more than ten languages through a portfolio of leading branded websites like and The Zacks Consensus Estimate for 2025 earnings has been revised upward by a cent to $1.07 per share in the past 30 days. GAMB has a VGM Score of A. Orion Group is a construction company that provides services on and off the water primarily in the continental United States, Alaska, Canada and the Caribbean Basin. The company's operating segment consists of the heavy civil marine construction segment and the commercial concrete segment. The Zacks Consensus Estimate for Orion Group's 2025 earnings has been revised upward by a cent to 17 cents per share over the past seven days. ORN has a VGM Score of A. Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and back-testing software. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit at: Follow us on Twitter: Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Contact: Jim Giaquinto Company: Phone: 312-265-9268 Email: pr@ Visit: provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SunOpta, Inc. (STKL) : Free Stock Analysis Report Orion Group Holdings, Inc. (ORN) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report Group Limited (GAMB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
17-07-2025
- Business
- Yahoo
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
For Immediate Release Chicago, IL – July 17, 2025 – Today, Zacks Equity Research discusses Catalyst Pharmaceuticals CPRX, Zevra Therapeutics ZVRA, Theravance Biopharma TBPH, Aldeyra Therapeutics ALDX and Larimar Therapeutics LRMR. Industry: Small Drugs Link: The uncertainty around tariffs and trade production measures has muted economic growth. President Trump has once again threatened to impose heavy tariffs, as high as 200%, on pharmaceutical imports. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at encouraging American pharmaceutical companies to shift their production back to the United States, primarily from European and Asian countries. Trump has said that drugmakers have about one to one and a half years to bring production back to the United States before the new tariffs are imposed. However, despite the threat of a 200% tariff, the biotech sector remained stable. The delay brings relief for the sector. Moreover, most global pharma companies have already committed to investing in boosting domestic manufacturing. Amid the tariff headwinds, the Zacks Medical-Drugs industry is showing promising trends backed by positive pipeline and regulatory developments. Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention. M&A activity also remains healthy. These factors should continue to drive stocks like Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics. Industry Description The Zacks Medical-Drugs industry comprises small and some medium-sized drug companies that make medicines for both human and veterinary use. We have a separate industry outlook discussion on big drugmakers. Small drugmakers have a limited portfolio of marketed drugs or no commercial-stage drugs at all. Some drugmakers are dependent on just one marketed drug or pipeline candidate. For such companies, upfront or milestone payments from collaboration partners — in most cases, their larger counterparts — are the main sources of revenues. These companies need ample free cash flow to fund their R&D activities. Factors Shaping the Future of the Medical-Drugs Industry The success or failure of key pipeline candidates in clinical studies can significantly drive the stock price of industry players. Successful innovation and product line extensions in important therapeutic areas and strong clinical study results may act as important catalysts for the stocks. These companies regularly seek external partners and collaborators for complementary strengths. A partnership deal with a popular drugmaker is a good sign about the potential of small pharma companies, especially when an equity investment is included in the deal. M&A deals are in full swing in the sector, signaling growth. For smaller companies, succeeding in a shifting global market and evolving healthcare landscape requires adopting innovative business models, investing in new technologies and increasing investments in personalized medicines. Over the past few years, scientific and technological advancements have made it possible to develop personalized therapies. Other than that, adoption and information exchange through the meaningful use of health IT, development of therapies that improve overall patient outcomes and investment in developing and emerging markets are some of the key priorities for drug companies. Artificial intelligence and machine learning techniques are being used for the rapid advancement of drug discovery and target identification processes. The smaller companies have their share of risk in the form of unstable cash flows. Also, the failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be huge setbacks for these smaller companies and significantly hurt their share prices. Zacks Industry Rank Indicates Bright Prospects The group's Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks. The Zacks Medical-Drugs industry currently carries a Zacks Industry Rank #96, which places it in the top 39% of the 245 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present you with a few top-ranked stocks to capitalize on the thriving prospects of the small and medium-sized drugmakers' space, let's take a look at the industry's recent stock-market performance and the valuation picture. Industry Versus S&P 500 and Sector The Zacks Medical-Drugs industry is a huge 155-stock group within the broader Medical sector. The industry has outperformed the Zacks Medical sector while slightly underperforming the S&P 500 so far this year. Stocks in this industry have collectively risen 5.6% year to date against the Zacks Medical sector's decrease of 2.9%. The Zacks S&P 500 composite has risen 6.9% in the said time frame. Industry's Current Valuation Based on the trailing 12 months price-to-sales ratio (P/S TTM), which is a commonly used multiple for valuing these small drugmakers, the industry is currently trading at 2.32, compared with the S&P 500's 5.66 and the Zacks Medical sector's 2.37. Over the last five years, the industry has traded as high as 3.56, as low as 1.93 and at the median of 2.42, as the chart below shows. 5 Drug Stocks to Bet On Catalyst Pharmaceuticals: Coral Gables, FL-based Catalyst Pharmaceuticals' lead drug is Firdapse, which is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS), an ultra-rare disease. The drug has been witnessing strong demand driven by increasing prescription rates and new patient starts. In January 2025, Catalyst settled Firdapse patent litigation with Teva, protecting the drug's exclusivity in the United States till Feb. 25, 2035. Agamree, its newest acquired muscle disorder drug, was launched in the U.S. market in 2024. With Agamree's approval and launch, Catalyst has further diversified its commercial portfolio. The stock of Catalyst Pharmaceuticals has risen 0.4% so far this year. The consensus estimate for 2025 earnings has risen from $2.23 per share to $2.25 per share over the past 60 days. The company has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Theravance Biopharma: Cayman Islands-based Theravance Biopharma generates revenues in the United States from its collaboration with Viatris related to the sales of Yupelri, a nebulized therapy for chronic obstructive pulmonary disease. The product has been witnessing a strong sales uptake owing to increased customer demand, resulting in increased collaboration revenues for Theravance. The company's ongoing restructuring initiatives are saving costs. Theravance is currently focusing on developing its pipeline candidate, ampreloxetine, a norepinephrine reuptake inhibitor for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy in the phase III CYPRESS study. The CYPRESS study is expected to complete patient enrollment by late summer of 2025. Top-line data from the same is expected six months after enrollment is completed. The stock of Theravance Biopharma has risen 22.6% so far this year. The consensus estimate for 2025 earnings has declined from 3 cents per share to 1 cent per share over the past 60 days. The company has a Zacks Rank #2. Larimar Therapeutics: CA-based Larimar Therapeutics is a clinical-stage company making medicines for rare diseases. Its lead pipeline candidate is nomlabofusp (CTI-1601), being developed as a potential treatment for Friedreich's ataxia (FA). Larimar Therapeutics plans to file a biologics license application seeking accelerated approval of nomlabofusp for FA in the second quarter of 2026. Larimar plans to expand the nomlabofusp clinical program to patients around the world with the initiation of a global phase III study. The company believes that nomlabofusp has the potential to be the first frataxin protein replacement therapy for patients with FA. The stock of Larimar Therapeutics has declined 18.3% so far this year. The consensus estimate for 2025 loss has narrowed from $1.90 per share to $1.89 per share over the past 60 days. The company has a Zacks Rank #2. Zevra Therapeutics: Early adoption of ZVRA's newly approved Miplyffa capsules for treating Niemann-Pick disease type C (NPC) has exceeded the company's expectations. Miplyffa was approved by the FDA in September 2024 as the first treatment for this ultra-rare disease. Zevra plans to file a regulatory application seeking approval of Miplyffa capsules in the EU in the second half of 2025. In April 2025, Zevra sold its Pediatric Rare Disease Priority Review Voucher ("PRV") for gross proceeds of $150 million, which has strengthened its cash position. The stock of Zevra Therapeutics has risen 53.4% so far this year. The earnings estimate for 2025 has risen from 31 cents per share to 76 cents per share over the past 60 days. The company has a Zacks Rank #2. Aldeyra Therapeutics: Burlington, MA-based Aldeyra Therapeutics is a leader in the development of RASP (reactive aldehyde species) modulators for the treatment of immune-mediated disease. Its late-stage pipeline candidates are reproxalap, a RASP modulator for the treatment of signs and symptoms of dry eye disease, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. In June, Aldeyra Therapeutics resubmitted a new drug application (NDA) to the FDA for reproxalap, including data from the Dry Eye Chamber study, which achieved the primary endpoint. The FDA had earlier issued a complete response letter to Aldeyra's NDA for reproxala in April, requiring the company to conduct an additional symptom study for resubmission. Its other product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743 and ADX-631. The stock of Aldeyra Therapeutics has declined 0.4% so far this year. The consensus estimate for 2025 loss has narrowed from $1.03 per share to 90 cents per share over the past 60 days. The company has a Zacks Rank #2. Research Chief Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report Larimar Therapeutics, Inc. (LRMR) : Free Stock Analysis Report Zevra Therapeutics, Inc. (ZVRA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Business Insider
04-06-2025
- Business
- Business Insider
Catalyst Pharmaceuticals CEO Daly buys 70,000 common shares
In a regulatory filing, Catalyst Pharmaceuticals (CPRX) president and CEO Richard Daly disclosed the purchase of 70,000 common shares of the company on May 30 at a price of $24.86 per share. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
09-05-2025
- Business
- Yahoo
Catalyst Pharmaceuticals Inc (CPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) reported a 43.6% year-over-year increase in total net revenues, reaching $141.4 million. The company maintains a strong cash position of $580.7 million, supporting long-term growth and strategic priorities. Firdapse showed a 25.3% year-over-year revenue increase, driven by strong adoption among newly diagnosed patients. Agamree's net product revenues increased significantly to $22 million, reflecting its first full year of commercial availability. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) reaffirmed its full-year total product revenue guidance of between $545 million to $565 million, indicating confidence in sustained growth. The company faces potential revenue decline for Fycompa due to the anticipated generic entry after May 23, 2025. There is ongoing litigation with two remaining first filers regarding generic entry, creating uncertainty around intellectual property protection. The cybersecurity incident in Q1 2024 affected prescription activity, although it has since normalized. The company anticipates increased cost of sales due to higher royalty obligations as product sales exceed certain thresholds. Despite strong performance, the company remains conservative in its revenue guidance for Firdapse, potentially underestimating growth opportunities. Warning! GuruFocus has detected 3 Warning Sign with CPRX. Q: How much of the 25% growth in Firdaps is due to current quarter strength versus last year's weakness due to the change in healthcare impact? Also, what is the proportion of patients on tablet versus oral suspension formulation for Firdaps? A: The growth is within the expected 15-20% range, even when accounting for the change in healthcare impact. Approximately 98% of patients are on the tablet formulation. - Jeff Del Carmen, Chief Commercial Officer Q: How is the uptake of Firdaps among small cell lung cancer patients trending, and what are the growth expectations for this segment? A: Currently, 20-25% of Firdaps patients are cancer-associated LEMS patients. The focus is on increasing diagnosis rates through BGCC antibody screening, with an expectation to grow this segment to 30-35% in the long term. - Jeff Del Carmen, Chief Commercial Officer Q: What are Catalyst's current thoughts on business development in the changing macro environment? A: Catalyst remains focused on immediately accretive opportunities. The current market dynamics present beneficial opportunities, and the strategy remains unaffected by regulatory changes. - Richard Daley, President and CEO Q: Can you provide insights into the Summit study for Agamry and what aspects of its profile will resonate with prescribers? A: The Summit study will focus on bone health, bone density, and cardiac effects, which are expected to confirm Agamry's differentiation. - Gary Innito, Chief Medical Officer Q: What is the current market penetration for Firdaps, and what initiatives are in place to increase it? A: The market penetration is about 25%, with significant upside potential. Initiatives to increase diagnosis, especially in cancer-associated LEMS, are expected to drive further growth. - Richard Daley, President and CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
30-04-2025
- Business
- Yahoo
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ('Catalyst' or 'Company') (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PT The webcast will be available under the Investors section on the Company's website, and a replay will be available for at least 14 days. About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies. For more information, please visit Catalyst's website at Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission ('SEC'), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. Source: Catalyst Pharmaceuticals, Inc. CONTACT: Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@ Media Contact David Schull, Russo Partners (858) 717-2310 in to access your portfolio
